However, recent evidence has shown that the hepatic response to FGF19 was impaired in NAFLD patients with a HOMA score ≥2.5 in contrast to a normal response in NAFLD patients with a HOMA score <2.5 [45]. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatotic liver disease.